Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study

[1]  Keith A. Johnson,et al.  Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease , 2013, Neurobiology of Aging.

[2]  Kewei Chen,et al.  Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study , 2012, The Lancet Neurology.

[3]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[4]  Olivier Salvado,et al.  Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. , 2012, Brain : a journal of neurology.

[5]  Paul Edison,et al.  Can target-to-pons ratio be used as a reliable method for the analysis of [11C]PIB brain scans? , 2012, NeuroImage.

[6]  Kewei Chen,et al.  Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. , 2011, Archives of neurology.

[7]  Eric Westman,et al.  Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation , 2011, Neurobiology of Aging.

[8]  Susan M Resnick,et al.  Longitudinal patterns of β-amyloid deposition in nondemented older adults. , 2011, Archives of neurology.

[9]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[10]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[11]  F. Lopera,et al.  Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study , 2011, The Lancet Neurology.

[12]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[13]  C. Rowe,et al.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.

[14]  P. Tariot,et al.  Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. , 2010, Biomarkers in medicine.

[15]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[16]  Masanori Nakagawa,et al.  High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. , 2009, Archives of neurology.

[17]  Tyler E. Benedum,et al.  Preclinical Properties of 18F-AV-45: A PET Agent for Aβ Plaques in the Brain , 2009, Journal of Nuclear Medicine.

[18]  G. Alexander,et al.  Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[19]  A. Paetau,et al.  PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. , 2008, Brain : a journal of neurology.

[20]  S. Aalto,et al.  Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. , 2008, Archives of neurology.

[21]  Keith A. Johnson,et al.  P2-366 Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees , 2006, Alzheimer's & Dementia.

[22]  A. Fleisher,et al.  Identification of Alzheimer disease risk by functional magnetic resonance imaging. , 2005, Archives of neurology.

[23]  S. DeKosky,et al.  Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[24]  R. Tanzi,et al.  The genetic epidemiology of neurodegenerative disease. , 2005, The Journal of clinical investigation.

[25]  R. Tanzi,et al.  Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective , 2005, Cell.

[26]  Alan C. Evans,et al.  Fast and robust parameter estimation for statistical partial volume models in brain MRI , 2004, NeuroImage.

[27]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[28]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[29]  J. Morris,et al.  Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage alzheimer’s disease , 2001, Journal of Molecular Neuroscience.

[30]  M N Cantwell,et al.  Does cerebral blood flow decline in healthy aging? A PET study with partial-volume correction. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  F. Lopera,et al.  Hallazgos neuropatológicos en la enfermedad de Alzheimer de inicio temprano (mutación E280A-PS1) , 1999 .

[32]  J Bohl,et al.  Staging of Alzheimer-Related Cortical Destruction , 1997, International Psychogeriatrics.

[33]  Rodger J. Elble,et al.  The distribution of amyloid β protein deposition in the corpus striatum of patients with Alzheimer's disease , 1997 .

[34]  A. Ruiz-Linares,et al.  Clinical Features of Early-Onset Alzheimer Disease in a Large Kindred With an E280A Presenilin-1 Mutation , 1997 .

[35]  S. Thibodeau,et al.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.

[36]  J. Yesavage,et al.  Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. , 1986 .

[37]  A. Hirano,et al.  Modified Bielschowsky stain and immunohistochemical studies on striatal plaques in Alzheimer's disease , 2004, Acta Neuropathologica.

[38]  H. Braak,et al.  Staging of Alzheimer-related cortical destruction. , 1997, International psychogeriatrics.

[39]  M A Pericak-Vance,et al.  Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. , 1993, Neurology.

[40]  B. Reisberg.  Functional assessment staging (FAST). , 1988, Psychopharmacology bulletin.

[41]  T. L. Brink,et al.  Clinical Gerontology: A Guide to Assessment and Intervention , 1986 .